Spots Global Cancer Trial Database for Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC

Official Title: A Phase II Study of Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced Hepatocellular Carcinoma Who Have Vascular Invasion With or Without Sorafenib-Experience in an HBV-endemic Area

Study ID: NCT04611165

Conditions

Advanced Hepatocellular Carcinoma

Interventions

Nivolumab

Study Description

Brief Summary: To investigate the efficacy and safety of nivolumab for patients with advanced HCC undergoing EBRT

Detailed Description: \<Treatment phase\> Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks. External beam radiotherapy begins 2-7 days after the first dose of nivolumab. The study drug is continued until disease progression, unacceptable toxicity, withdrawal of consent or study closure. \<Follow-Up phase \> After the treatment phase, subjects will undergo follow up for survival every 12 weeks (± 7 days) from the last dose or the use of other anticancer treatments and/or therapies, and the survival follow up will be performed for at least 18 months after the enrollment of the last subject. The patient will be followed for survival follow up and the use of other anticancer treatments and/or therapies. Based on the assumed dropout rate of 12%, a total of 50 subjects need to perform the study (50=44/(1-0.12))